Clinical Study | Office of Clinical Research

Bn42083 A Phase IIIb Multicenter, Randomized, Double-Blind, Controlled Study To Evaluate The Efficacy, Safety And Pharmacokinetics Of A Higher Dose Of Ocrelizumab In Adults With Primary Progressive Multiple Sclerosis

Posted Date: Feb 15, 2021

Investigator: Aram Zabeti
Specialties: Multiple Sclerosis, Neurology
Type of Study: Drug

The primary efficacy objective is to demonstrate the superiority of a higher dose of ocrelizumab over the approved dose of ocrelizumab as assessed by risk reduction in cCDP sustained for at least 12 weeks.

Criteria:

Participant Must Be Between 18-55 That Has Been Diagnosed With Primary Progressive Multiple Sclerosis (Ppms) And Be Neurologically Stable For At Least 30 Days Prior To Randomization And Baseline Assessments.

Keywords:

Primary Progressive Multiple Sclerosis, Neurology, Ocrelizumab

For More Information:

Tiffany Rupert
513-558-0269
tiffany.rupert@uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List